Related Experiment Video

Updated: Jun 23, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor

Kouji Izumi1, Atsushi Mizokami, You Qiang Li

  • 1Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa 920-8641, Japan.

The Prostate
|May 13, 2009
PubMed
Abstract

Insights

Tranilast shows anti-tumor effects on prostate cancer by inhibiting cell proliferation and inducing apoptosis. It also suppresses bone metastasis-related factors, suggesting its potential for treating hormone-refractory prostate cancer (HRPC).

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Tranilast, an anti-allergic agent, exhibits anti-tumor properties.
  • Prostate cancer treatment remains a significant challenge, especially in advanced stages.

Purpose of the Study:

  • To investigate the anti-tumor mechanisms of tranilast in prostate cancer.
  • To evaluate tranilast's efficacy in hormone-refractory prostate cancer (HRPC).

Main Methods:

  • In vitro studies on prostate cancer cell lines and bone-derived stromal cells.
  • In vivo studies using severe combined immunodeficient (SCID) mice models.
  • Clinical investigation in patients with advanced HRPC.

Main Results:

  • Tranilast inhibited prostate cancer cell proliferation and induced cell cycle arrest and apoptosis.
  • Tranilast suppressed transforming growth factor beta1 (TGF-beta1) secretion from bone-derived stromal cells.
  • Clinical trials showed inhibition of PSA progression in HRPC patients.

Conclusions:

  • Tranilast demonstrates direct anti-cancer effects on prostate cancer cells.
  • Tranilast may mitigate bone metastasis by inhibiting TGF-beta1-associated osteoblastic changes.
  • Tranilast shows promise as a therapeutic agent for HRPC.

Related Concept Videos

Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...